Eli Lilly and Co (BSP:LILY34)
R$ 154 -1.68 (-1.08%) Market Cap: 4.43 Tn Enterprise Value: 4.59 Tn PE Ratio: 87.14 PB Ratio: 50.94 GF Score: 77/100

Q2 2024 Eli Lilly and Co Earnings Call Transcript

Aug 08, 2024 / 02:00PM GMT
Release Date Price: R$157.35 (+9.87%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2024 Earnings Call. (Operator Instructions) I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.

Joe Fletcher
Eli Lilly and Co - Senior Vice President of Investor Relations

Thanks, Paul. Good morning, everyone. Thanks for joining us for Eli Lilly and Company's Q2 2024 Earnings Call. I'm Joe Fletcher, Senior Vice President of Investor Relations. And joining me on today's call are Dave Ricks, Lilly's Chair and CEO; Dr. Dan Skovronsky, Chief Scientific Officer and President of Lilly Immunology; Gordon Brooks, Interim Chief Financial Officer; Anne White, President of Lilly Neuroscience; Ilya Yuffa, President of Lilly International; Jake Van Naarden, President of Lilly Oncology; and Patrik Jonsson, President of Lilly Cardiometabolic Health and Lilly USA. And we're also joined by Michala Irons, Mike Sprengnether and Lauren Zierke of the IR team. During this conference call, we anticipate making projections and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot